Evogene Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
EVGN
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 14.99M 55.21M | Sales 2025 * | 25.85M 95.2M | Capitalization | 33.16M 122M |
---|---|---|---|---|---|
Net income 2024 * | -22M -81.02M | Net income 2025 * | -19M -69.97M | EV / Sales 2024 * | 2.21 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.28 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 44.44B | |
+41.98% | 40.03B | |
-10.06% | 37.68B | |
+31.15% | 31.46B | |
-7.79% | 27.29B | |
+13.32% | 26.29B | |
+43.05% | 13.8B | |
+31.28% | 12.46B | |
-7.41% | 11.26B |